The gut microbiota in patients with polycythemia vera is distinct from that of healthy controls and varies by treatment.

ABSTRACT: Chronic inflammation is believed to play an important role in the development and disease progression of polycythemia vera (PV). Because an association between gut microbiota, hematopoiesis, and inflammation is well established, we hypothesized that patients with PV have a gut microbiota distinct from healthy control participants (HCs). Recombinant interferon alfa 2 (IFN-α2)-treatment of patients with PV is reportedly disease modifying in terms of normalization of elevated blood cell counts in concert with a reduction in the JAK2V617F allelic burden. Therefore, we hypothesized that patients treated with IFN-α2 might have a composition of the gut microbiota toward normalization. Herein, via amplicon-based next-generation sequencing of the V3 to V4 regions of the 16S ribosomal RNA gene, we r

SUBMITTER: Eickhardt-Dalboge CS 

PROVIDER: S-EPMC10362542 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature